<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121770</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00021052</org_study_id>
    <secondary_id>112972</secondary_id>
    <nct_id>NCT01121770</nct_id>
  </id_info>
  <brief_title>&quot;Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction&quot;</brief_title>
  <acronym>FONDA PK</acronym>
  <official_title>Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a preventative dose of study drug, Arixtra® for
      patients with kidney disease. We will measure the blood levels of Arixtra® in patients with
      kidney disease and develop guidelines for dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood samples to measure specific Arixtra® concentration</measure>
    <time_frame>• Three blood samples for PK analyses will be obtained within the 24 hour period immediately following either the third or fourth consecutive dose of Arixtra</time_frame>
    <description>peak level will be collected 2-3 hours after the dose interval level will be collected between peak and midpoint midpoint level will be collected 12 hours after the dose interval level will be collected midpoint and trough trough level will be collected just prior to the next scheduled dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of bleeding events and new thrombotic events</measure>
    <time_frame>Daily assessments will be made for bleeding and thrombosis</time_frame>
    <description>events will be used to compare to rates in patients without renal dysfunction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Arixtra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux sodium injection</intervention_name>
    <description>1.5mg subcutaneously every day</description>
    <arm_group_label>Arixtra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatients who are 18 years or older

          -  estimated creatinine clearances between 20-50 ml/min

          -  current hospitalization for a cancer-related abdominal, breast surgery or elective
             orthopedic surgery

          -  able to give informed consent

          -  need for prophylactic anticoagulant therapy for increased risk of a thrombotic episode

        Exclusion Criteria: Use of the following

          -  clopidogrel, aspirin, or NSAID usage,(usage is prohibited while patients are
             participating in the study)

          -  body weight &lt; 50 kg

          -  anticoagulation therapy for thrombosis or other indication

          -  pregnant or breast-feeding

          -  hypersensitivity to Arixtra®

          -  thrombocytopenia associated with a positive in vitro test for anti-platelet antibody
             in the presence of Arixtra®

          -  bacterial endocarditis

          -  brain malignancy

          -  increased risk of bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Ortel, M.D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://htc.medicine.duke.edu/</url>
    <description>The Duke Hemostasis &amp; Thrombosis Center provides a multidisciplinary approach to the diagnosis and management of a wide variety of hemostatic disorders and is a leader in basic research effort. Click here for more information about this study.</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

